Indian Firms Push For Favorable USTR IPR Review

 
• By Anju Ghangurde

It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.

Pills world map
INDIAN FIRMS SAY THE IPR REGIME HAS IMPROVED IN THE COUNTRY

More from Legal & IP

More from Pink Sheet